Novel Therapies in Oncology: An Individualized Approach

Activity Summary

Required reading for all learners: Implicit Bias impacts patient outcomes

This article reviews novel therapies in oncology which have made a profound difference in the treatment of cancer. The new approaches described include immune checkpoint inhibitors, antibody-drug conjugates, protein kinase inhibitors, bispecific antibodies and tumor-treating fields. The article explains each agent’s mechanisms of action and the management of adverse events that require critical care interventions.

Objectives

Explain novel therapies in oncology and their mechanisms of action
Describe potential adverse events related to novel therapies in oncology that may require critical care team management
Identify patient care considerations when caring for a patient with a tumor treating fields device

Continuing Education Disclosure Statement

Criteria for Awarding Contact Hours

Learners must complete the entire activity and the associated evaluation AND read Implicit Bias impacts patient outcomes. No partial credit will be awarded.

Accreditation

American Association of Critical-Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Provider approved by the California Board of Registered Nursing, Provider number CEP 1036, for {contactHours} contact hours.

Disclosures

The Nurse Planner has determined that no individuals with the ability to control content of this activity have relevant relationships with ineligible companies.

Activities with pharmacotherapeutic credit are to assist the APRN in fulfilling their education requirements for licensure and certification renewals.

Refund Policy

Continuing Education Activities are nonrefundable.